Paying users zone. Data is hidden behind hidden.

  • Get 1-month access to Abbott Laboratories for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Microsoft Excel LibreOffice Calc

Abbott Laboratories (ABT)


Cash Flow Statement

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Abbott Laboratories, consolidated cash flow statement

US$ in millions

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net earnings hidden hidden hidden hidden hidden
Depreciation hidden hidden hidden hidden hidden
Amortization of intangible assets hidden hidden hidden hidden hidden
Share-based compensation hidden hidden hidden hidden hidden
Impact of currency devaluation hidden hidden hidden hidden hidden
Amortization of inventory step-up hidden hidden hidden hidden hidden
Investing and financing (gains) losses, net hidden hidden hidden hidden hidden
Loss on extinguishment of debt hidden hidden hidden hidden hidden
Amortization of bridge financing fees hidden hidden hidden hidden hidden
Gains on sale of businesses hidden hidden hidden hidden hidden
Mylan N.V. equity investment adjustment hidden hidden hidden hidden hidden
Gain on sale of Mylan N.V. shares hidden hidden hidden hidden hidden
Trade receivables hidden hidden hidden hidden hidden
Inventories hidden hidden hidden hidden hidden
Prepaid expenses and other assets hidden hidden hidden hidden hidden
Trade accounts payable and other liabilities hidden hidden hidden hidden hidden
Income taxes hidden hidden hidden hidden hidden
(Increase) decrease in operating capital hidden hidden hidden hidden hidden
Adjustments to reconcile earnings to net cash from operating activities hidden hidden hidden hidden hidden
Net cash from operating activities hidden hidden hidden hidden hidden
Acquisitions of property and equipment hidden hidden hidden hidden hidden
Acquisitions of businesses and technologies, net of cash acquired hidden hidden hidden hidden hidden
Proceeds from business dispositions hidden hidden hidden hidden hidden
Proceeds from the sale of Mylan N.V. shares hidden hidden hidden hidden hidden
Purchases of investment securities hidden hidden hidden hidden hidden
Proceeds from sales of investment securities hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Net cash (used in) from investing activities hidden hidden hidden hidden hidden
Proceeds from issuance (repayments) of short-term debt and other hidden hidden hidden hidden hidden
Proceeds from issuance of long-term debt and debt with maturities over 3 months hidden hidden hidden hidden hidden
Repayments of long-term debt and debt with maturities over 3 months hidden hidden hidden hidden hidden
Payment of bridge financing fees hidden hidden hidden hidden hidden
Purchase of Alere preferred stock hidden hidden hidden hidden hidden
Acquisition and contingent consideration payments related to business acquisitions hidden hidden hidden hidden hidden
Purchases of common shares hidden hidden hidden hidden hidden
Proceeds from stock options exercised hidden hidden hidden hidden hidden
Dividends paid hidden hidden hidden hidden hidden
Net cash from (used in) financing activities hidden hidden hidden hidden hidden
Effect of exchange rate changes on cash and cash equivalents hidden hidden hidden hidden hidden
Net increase (decrease) in cash and cash equivalents hidden hidden hidden hidden hidden
Cash and cash equivalents, beginning of year hidden hidden hidden hidden hidden
Cash and cash equivalents, end of year hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-27).

Cash flow statement item Description The company
Net cash from operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Abbott Laboratories’s net cash from operating activities increased from 2016 to 2017 and from 2017 to 2018.
Net cash (used in) from investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Abbott Laboratories’s net cash (used in) from investing activities decreased from 2016 to 2017 but then increased from 2017 to 2018 not reaching 2016 level.
Net cash from (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Abbott Laboratories’s net cash from (used in) financing activities decreased from 2016 to 2017 and from 2017 to 2018.